Search

Your search keyword '"Gattino, Francesca"' showing total 28 results
Start Over Author "Gattino, Francesca"
28 results on '"Gattino, Francesca"'

1. Data Supplement from CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA

Author

Riccardo, Federica, primary, Iussich, Selina, primary, Maniscalco, Lorella, primary, Lorda Mayayo, Saray, primary, La Rosa, Giuseppe, primary, Arigoni, Maddalena, primary, De Maria, Raffaella, primary, Gattino, Francesca, primary, Lanzardo, Stefania, primary, Lardone, Elena, primary, Martano, Marina, primary, Morello, Emanuela, primary, Prestigio, Simone, primary, Fiore, Alessandra, primary, Quaglino, Elena, primary, Zabarino, Sara, primary, Ferrone, Soldano, primary, Buracco, Paolo, primary, and Cavallo, Federica, primary

Published
2023
Full Text
View/download PDF

4. A Retrospective Multicentric Study of Electrochemotherapy in the Treatment of Feline Nasal Planum Squamous Cell Carcinoma

Author

Simčič, Petra, primary, Pierini, Alessio, additional, Lubas, George, additional, Lowe, Ron, additional, Granziera, Valentina, additional, Tornago, Raimondo, additional, Valentini, Fabio, additional, Alterio, Giulia, additional, Cochi, Matteo, additional, Rangel, Marcelo Monte Mor, additional, de Oliveira, Krishna Duro, additional, Ostrand Freytag, Jennifer, additional, Quadros, Priscila Gil, additional, Sponza, Enrico, additional, Gattino, Francesca, additional, Impellizeri, Joseph A., additional, and Torrigiani, Filippo, additional

Published
2021
Full Text
View/download PDF

5. Supplemental_Figure – Supplemental material for Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma

Author

Riccardo, Federica, Tarone, Lidia, Iussich, Selina, Giacobino, Davide, Arigoni, Maddalena, Sammartano, Federica, Morello, Emanuela, Martano, Marina, Gattino, Francesca, Maria, Raffaella De, Soldano Ferrone, Buracco, Paolo, and Cavallo, Federica

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supplemental_Figure for Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma by Federica Riccardo, Lidia Tarone, Selina Iussich, Davide Giacobino, Maddalena Arigoni, Federica Sammartano, Emanuela Morello, Marina Martano, Francesca Gattino, Raffaella De Maria, Soldano Ferrone, Paolo Buracco and Federica Cavallo in Therapeutic Advances in Medical Oncology

Published
2019
Full Text
View/download PDF

6. Supplemental Material, DS1_VET_10.1177_0300985818806967 - Expression of the Short Form of RON/STK in Feline Mammary Carcinoma

Author

Maniscalco, Lorella, Guil-Luna, Silvia, Iussich, Selina, Gattino, Francesca, Trupia, Calogero, Millan, Yolanda, Mulas, Juana Martín De Las, Cespedez, Raquel Sanchez, K. Saeki, Accornero, Paolo, and Maria, Raffaella De

Subjects
70706 Veterinary Medicine, FOS: Clinical medicine, FOS: Veterinary sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental Material, DS1_VET_10.1177_0300985818806967 for Expression of the Short Form of RON/STK in Feline Mammary Carcinoma by Lorella Maniscalco, Silvia Guil-Luna, Selina Iussich, Francesca Gattino, Calogero Trupia, Yolanda Millan, Juana Martín de Las Mulas, Raquel Sanchez Cespedez, K. Saeki, Paolo Accornero, and Raffaella De Maria in Veterinary Pathology

Published
2018
Full Text
View/download PDF

7. In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models

Author

Sánchez‐Céspedes, Raquel, primary, Accornero, Paolo, additional, Miretti, Silvia, additional, Martignani, Eugenio, additional, Gattino, Francesca, additional, Maniscalco, Lorella, additional, Gola, Cecilia, additional, Iussich, Selina, additional, Martano, Marina, additional, Morello, Emanuela, additional, Buracco, Paolo, additional, Aresu, Luca, additional, and Maria, Raffaella De, additional

Published
2019
Full Text
View/download PDF

8. Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma

Author

Riccardo, Federica, primary, Tarone, Lidia, additional, Iussich, Selina, additional, Giacobino, Davide, additional, Arigoni, Maddalena, additional, Sammartano, Federica, additional, Morello, Emanuela, additional, Martano, Marina, additional, Gattino, Francesca, additional, Maria, Raffaella De, additional, Ferrone, Soldano, additional, Buracco, Paolo, additional, and Cavallo, Federica, additional

Published
2019
Full Text
View/download PDF

9. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination

Author

Piras, Lisa Adele, Riccardo, Federica, Iussich, Selina, Maniscalco, Lorella, Gattino, Francesca, Martano, Marina, Morello, Emanuela Maria, LORDA MAYAYO, Saray, Rolih, Valeria, Garavaglia, F., DE MARIA, Raffaella, Lardone, Elena, Collivignarelli, F., Mignacca, D., Giacobino, D., Ferrone, S., Cavallo, Federica, and Buracco, Paolo

Subjects
Male, CSPG4, comparative oncology, canine oral malignant melanoma, adjuvant immunotherapy, DNA electroporation, Adjuvants, Immunologic, Animals, Cancer Vaccines, Chondroitin Sulfate Proteoglycans, Combined Modality Therapy, Dog Diseases, Dogs, Female, Melanoma, Mouth Neoplasms, Article, Immunologic, canine oral malignant melanoma, adjuvant immunotherapy, CSPG4, DNA electroporation, comparative oncology, Adjuvants
Abstract

Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards adjuvant electrovaccination with human chondroitin sulfate proteoglycan-4 (hCSPG4)-encoded plasmid in 23 dogs with resected II/III-staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-positive oral cMM. Vaccination resulted in 6-, 12-, 18- and 24-month survival rate of 95.6, 73.9, 47.8 and 30.4%, respectively [median survival time (MST) 684 days, range 78–1694, 8 of 23 dogs alive] and 6-, 12-, 18- and 24-month disease-free interval (DFI) rate of 82.6, 47.8, 26.1 and 17.4%, respectively (DFI 477 days, range 50–1694). Non-vaccinated dogs showed 6-, 12-, 18- and 24-month survival rate of 63.2, 26.3, 15.8 and 5.3%, respectively (MST 200 days, range 75–1507, 1 of 19 dogs alive) and 6-, 12-, 18- and 24-month DFI rate of 52.6, 26.3, 10.5 and 5.3%, respectively (DFI 180 days, range 38–1250). Overall survival and DFI of vaccinated dogs was longer in those

Published
2017

10. In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models.

Author

Sánchez‐Céspedes, Raquel, Accornero, Paolo, Miretti, Silvia, Martignani, Eugenio, Gattino, Francesca, Maniscalco, Lorella, Gola, Cecilia, Iussich, Selina, Martano, Marina, Morello, Emanuela, Buracco, Paolo, Aresu, Luca, and Maria, Raffaella De

Subjects
CELL lines, CELL growth, PROTEIN-tyrosine kinases, PHOSPHATES, BODY weight, DASATINIB
Abstract

Canine osteosarcoma (OSA) is the most common primary malignant bone tumour in dogs, and it has a high metastatic rate and poor prognosis. Toceranib phosphate (TOC; Palladia, Zoetis) is a veterinary tyrosine kinase inhibitor that selectively inhibits VEGFR‐2, PDGFRs and c‐Kit, but its efficacy is not yet fully understood in the treatment of canine OSA. Here, we evaluated the functional effects of TOC on six OSA cell lines by transwell, wound healing and colony formation assays. Subsequently, two cell lines (Wall and Penny) were selected and were inoculated in mice by intrafemoral injection to develop an orthotopic xenograft model of canine OSA. For each cell line, 30 mice were xenografted; half of them were used as controls, and the other half were treated with TOC at 40 mg/kg body weight for 20 days. TOC inhibited cell growth of all cell lines, but reduced invasion and migration was only observed in Penny and Wall cell lines. In mice engrafted with Penny cells and subjected to TOC treatment, decreased tumour growth was observed, and PDGFRs and c‐Kit mRNA were downregulated. Immunohistochemical analyses demonstrated a significant reduction of Ki67 staining in treated mice when compared to controls. The results obtained here demonstrate that TOC is able to slightly inhibit cell growth in vitro, while its effect is evident only in a Penny cell xenograft model, in which TOC significantly reduced tumour size and the Ki67 index without modifying apoptosis markers. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

11. Expression of the Short Form of RON/STK in Feline Mammary Carcinoma

Author

Maniscalco, Lorella, primary, Guil-Luna, Silvia, additional, Iussich, Selina, additional, Gattino, Francesca, additional, Trupia, Calogero, additional, Millan, Yolanda, additional, de Las Mulas, Juana Martín, additional, Cespedez, Raquel Sanchez, additional, Saeki, K., additional, Accornero, Paolo, additional, and De Maria, Raffaella, additional

Published
2018
Full Text
View/download PDF

12. PDGFR-α, PDGFR-β, VEGFR-2 and CD117 expression in canine mammary tumours and evaluation of the in vitro effects of toceranib phosphate in neoplastic mammary cell lines

Author

Gattino, Francesca, primary, Maniscalco, Lorella, additional, Iussich, Selina, additional, Biasato, Ilaria, additional, Martano, Marina, additional, Morello, Emanuela, additional, Gola, Cecilia, additional, Millán Ruiz, Yolanda, additional, Saeki, Nobuo, additional, Buracco, Paolo, additional, Martín de las Mulas, Juana, additional, and De Maria, Raffaella, additional

Published
2018
Full Text
View/download PDF

17. Expression of the Short Form of RON/STK in Feline Mammary Carcinoma.

Author

Maniscalco, Lorella, Guil-Luna, Silvia, Iussich, Selina, Gattino, Francesca, Trupia, Calogero, Millan, Yolanda, de Las Mulas, Juana Martín, Cespedez, Raquel Sanchez, Saeki, K., Accornero, Paolo, and De Maria, Raffaella

Subjects
CARCINOMA
Abstract

RON is a tyrosine kinase receptor activated by the macrophage-stimulating protein (MSP) ligand that is overexpressed in human breast cancer. In humans, RON protein can be present in different isoforms, and the most studied isoform is represented by the short form of RON (sf-RON), which is generated by an alternative promoter located in intron 10 of the RON complementary DNA (cDNA). It plays an important role in breast cancer progression. Considering the many similarities between feline mammary carcinoma (FMC) and human breast cancer, the aim of this study was to investigate the expression of both RON and MSP in FMCs and to identify the presence of the sf-RON transcript. Tissue samples of spontaneous mammary tumors were collected from 60 queens (10 benign lesions, 50 carcinomas). All of the samples were tested for RON and MSP expression by immunohistochemistry; moreover, RNA was extracted from paraffin-embedded tissue samples, and the cDNA was tested by reverse transcription–polymerase chain reaction (RT-PCR) to identify the presence of sf-RON. Immunohistochemistry detected the expression of RON and MSP in 34 of 50 (68%) and 29 of 50 (58%) FMCs, respectively. RT-PCR revealed the presence of the short-form in 18 of 47 (38%) FMCs. This form originates, as in humans, from an alternative promoter (P2), and it codes for the proper feline short form (sf-RON). sf-RON expression was associated with poorly differentiated tumors and with a shorter disease-free (P < .05; hazard ratio [HR], 2.2) period and a shorter survival (P < .05; HR, 2.2). These results support FMC as a suitable model in comparative oncology and identify sf-RON expression as potential predictor of outcomes for this disease. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

24. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009–2014)

Author

Stefanello, Damiano, primary, Buracco, Paolo, additional, Sabattini, Silvia, additional, Finotello, Riccardo, additional, Giudice, Chiara, additional, Grieco, Valeria, additional, Iussich, Selina, additional, Tursi, Massimiliano, additional, Scase, Timothy, additional, Di Palma, Stefano, additional, Bettini, Giuliano, additional, Ferrari, Roberta, additional, Martano, Marina, additional, Gattino, Francesca, additional, Marrington, Mary, additional, Mazzola, Monica, additional, Elisabetta Vasconi, Maria, additional, Annoni, Maurizio, additional, and Marconato, Laura, additional

Published
2015
Full Text
View/download PDF

25. CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA

Author

Riccardo, Federica, primary, Iussich, Selina, additional, Maniscalco, Lorella, additional, Lorda Mayayo, Saray, additional, La Rosa, Giuseppe, additional, Arigoni, Maddalena, additional, De Maria, Raffaella, additional, Gattino, Francesca, additional, Lanzardo, Stefania, additional, Lardone, Elena, additional, Martano, Marina, additional, Morello, Emanuela, additional, Prestigio, Simone, additional, Fiore, Alessandra, additional, Quaglino, Elena, additional, Zabarino, Sara, additional, Ferrone, Soldano, additional, Buracco, Paolo, additional, and Cavallo, Federica, additional

Published
2014
Full Text
View/download PDF

26. PDGFs and PDGFRs in canine osteosarcoma: New targets for innovative therapeutic strategies in comparative oncology

Author

LS Pathobiologie, dPB RMSC, Maniscalco, Lorella, Iussich, Selina, Morello, Emanuela, Martano, Marina, Biolatti, Bartolomeo, Riondato, Fulvio, Salda, Leonardo Della, Romanucci, Mariarita, Malatesta, Daniela, Bongiovanni, Laura, Tirrito, Federica, Gattino, Francesca, Buracco, Paolo, De Maria, Raffaella, LS Pathobiologie, dPB RMSC, Maniscalco, Lorella, Iussich, Selina, Morello, Emanuela, Martano, Marina, Biolatti, Bartolomeo, Riondato, Fulvio, Salda, Leonardo Della, Romanucci, Mariarita, Malatesta, Daniela, Bongiovanni, Laura, Tirrito, Federica, Gattino, Francesca, Buracco, Paolo, and De Maria, Raffaella

Published
2013

27. Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas

Author

Maniscalco, Lorella, primary, Millán, Yolanda, additional, Iussich, Selina, additional, Denina, Mauro, additional, Sánchez-Céspedes, Raquel, additional, Gattino, Francesca, additional, Biolatti, Bartolomeo, additional, Sasaki, Nobuo, additional, Nakagawa, Takayuki, additional, Di Renzo, Maria Flavia, additional, de las Mulas, Juana Martín, additional, and De Maria, Raffaella, additional

Published
2013
Full Text
View/download PDF

28. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009–2014)

Author

Damiano Stefanello, T. J. Scase, Mary Marrington, Maria Elisabetta Vasconi, Monica Mazzola, Paolo Buracco, Maurizio Annoni, Marina Martano, Roberta Ferrari, Chiara Giudice, Stefano Di Palma, Laura Marconato, Massimiliano Tursi, Riccardo Finotello, Valeria Grieco, Silvia Sabattini, Giuliano Bettini, Francesca Gattino, Selina Iussich, Stefanello, Damiano, Buracco, Paolo, Sabattini, Silvia, Finotello, Riccardo, Giudice, Chiara, Grieco, Valeria, Iussich, Selina, Tursi, Massimiliano, Scase, Timothy, Di Palma, Stefano, Bettini, Giuliano, Ferrari, Roberta, Martano, Marina, Gattino, Francesca, Marrington, Mary, Mazzola, Monica, Vasconi, Maria Elisabetta, Annoni, Maurizio, and Marconato, Laura

Subjects
Male, Pathology, medicine.medical_specialty, Skin Neoplasms, Veterinary. oncology, dog, mast cell tumor, histological grading, Veterinary oncology, Newly diagnosed, Mast cell tumors, Metastasis, Dogs, Animals, Medicine, Dog Diseases, Grading (tumors), cane, Retrospective Studies, mastocitoma cutaneo, General Veterinary, business.industry, Mastocytoma, medicine.disease, cane, mastocitoma cutaneo, grado istologico, metastasi, prognosi, Female, metastasi, Neoplasm Grading, grado istologico, business, prognosi
Abstract

Objective—To compare the Kiupel (2 categories) and Patnaik (3 categories) histologic grading systems for predicting the presence of metastasis at the time of initial examination in dogs with cutaneous mast cell tumors (MCTs). Design—Retrospective case series. Animals—386 client-owned dogs with cutaneous MCTs. Procedures—Medical records of dogs with newly diagnosed, histologically confirmed cutaneous MCTs that had undergone complete clinical staging were reviewed for clinical and histopathologic data. Results—All Patnaik grade 1 MCTs (n = 52) were classified as Kiupel low-grade MCTs, and all Patnaik grade 3 MCTs (43) were classified as Kiupel high-grade MCTs. Of the 291 Patnaik grade 2 MCTs, 243 (83.5%) were classified as Kiupel low-grade tumors, and 48 (16.5%) were classified as Kiupel high-grade MCTs. Dogs with Patnaik grade 3 MCTs were significantly more likely to have metastases at the time of initial examination than were dogs with grade 1 or 2 MCTs (OR, 5.46), and dogs with Kiupel high-grade MCTs were significantly more likely to have metastases than were dogs with Kiupel low-grade MCTs (OR, 2.54). However, 3 of 52 (5.8%) dogs with Patnaik grade 1 tumors, 48 of 291 (16.5%) dogs with Patnaik grade 2 tumors, and 44 of 295 (14.9%) dogs with Kiupel low-grade tumors had metastatic disease. Conclusions and Clinical Relevance—Findings indicated that in dogs with cutaneous MCTs, prognostication should not rely on histologic grade alone, regardless of grading system used, but should take into account results of clinical staging.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results